Important Information

THIS WEBSITE IS INTENDED FOR INSTITUTIONAL INVESTORS who are U.S. residents ONLY; not intended for access or distribution to retail investors.

 

In order to access the Capital Group U.S. Institutional website (the “Site”), please read the following information and affirm by clicking the accept button that you have read and understand the information provided.

 

You must attest that you meet the qualifications of an institutional investor as described herein and accept these Terms and Conditions in order to access the Site. Some content may require additional registration for access.

 

The Site is solely intended for U.S. residents who are institutional investors or are acting on behalf of an institutional investor who has agreed to these Terms and Conditions. Institutional investors include, but are not limited to any person acting on behalf of/any pension fund, financial intermediary, consultant, endowment and foundation, bank, savings and loan association, insurance company, investment company registered under the Investment Company Act of 1940, investment adviser registered with the U.S. Securities and Exchange Commission or under applicable state law, government entity, entity with total assets of at least $50 million, employee benefit or qualified retirement plan with at least 100 participants, defined contribution/benefit plan, and qualified client or purchaser as defined by the U.S. Securities and Exchange Commission. By agreeing to these Terms and Conditions you are affirming your understanding that the Site is not intended for retail investors, individual plan participants or others who may not possess the financial sophistication to independently understand the content nor should it be redistributed to such persons.

 

You understand that the Site does not constitute advice of any nature, including fiduciary investment advice by Capital Group or its associates.

 

The reference to “Capital Group” used herein includes The Capital Group Companies, Inc., and its affiliates.

Categories
China
China: What could drive its markets in 2023
Victor Kohn
Equity Portfolio Manager
Steve Watson
Equity Portfolio Manager
Kent Chan
Equity Investment Director

As nearly three years of lockdowns come to an end in China, will 2023 be a turning point for equity investors?


Without a doubt, China’s equity risk premium is higher than other markets. As investment professionals with more than 25 years of experience following China, we believe the higher premium is due to the government’s repeated intervention and influence in the economy and markets, as well as geopolitical uncertainty. We also recognize that China’s economic recovery could be uneven and trade-related tensions with the U.S. will likely persist.


However, China’s equities markets have been rallying this year on the country’s abrupt departure from strict COVID policies. Some sectors have been buoyed by more supportive measures for the property market and encouraging regulatory developments for technology companies. We’ve learned from experience that volatility can mask buying opportunities in China. We believe this could be one of those times, particularly for select companies well positioned for an economic rebound, but also for those that remain aligned with the Common Prosperity goals of the administration.


Here are a few themes to consider for investing in China and why we are constructive:


1. Reopening could be a positive catalyst for valuations


China’s departure from its zero-COVID policy removes a headwind to stocks and could be a catalyst for a positive rerating of Chinese equities. The MSCI China Index has already surged more than 50% (as of January 23) after reaching a multiyear low October 31, 2022, and we believe it has more room to run. Valuations for almost all sectors are still trading below their 10-year average on a consensus price-to-earnings (P/E) basis for the next 12 months. We don’t anticipate the market will rally indefinitely, but we sense downside risks have lessened, given that sentiment had become so dire since 2021.


The ability for people to move more freely should trigger a change in consumer behavior and lead to a recovery in domestic consumption. Beneficiaries of this shift will likely be hotel companies, online travel firms, airport operators and luxury goods makers. Airports are busy again as people seek to travel inside and outside the country. There’s been a surge in hotel bookings in China’s larger cities, and consumers are flocking back to shopping malls. 


Many sectors trade at steep discounts

Chart shows forward price-to-earnings ratios for sectors in the MSCI China Index and compares them against the 10-year average. Health care is trading 34% above its 10-year average, while the communications services and consumer discretionary sectors are trading 10% and 5% above their 10-year averages. By contrast, energy is 46% below its 10-year average. Information technology is 41% below its 10-year average. Financials is 30% below its 10-year average. Industrials is 22% below its 10-year average. Utilities is 19% below its 10-year average. Materials is 16% below its 10-year average, and consumer staples is 7% below its 10-year average.

Sources: MSCI, RIMES. Forward price-to-earnings ratio reflects the current share price relative to the consensus estimate for earnings per share on a forward 12-month basis. Data as of November 30, 2022.

Increased mobility may also benefit certain financial services providers whose sales agents rely on face-to-face meetings to drive new business. Casino operators in Macau, where travel is opening up after heavy restrictions, could benefit too. 


We think a cyclical recovery could boost the outlook for China’s larger banks, which on a P/E basis currently trade for three or four times consensus earnings expectations for the next 12 months. Valuations for Chinese banks have been depressed for many years. But they compressed further in 2022 on China’s weak growth and liquidity crunch in the property market.


2. Government is committed to stabilizing the property market


As part of its message that “housing is for living, not for speculation,” Beijing has sought to contain the rapid appreciation in residential property prices and reduce excess leverage. However, its various policy decisions have not always had the intended outcome. Many property developers are struggling financially, some have defaulted on debt payments, and homebuyers have become more cautious.


Recent actions have made it clear that the government recognizes it has to fix the property sector, which represents about 25% of GDP and roughly 60% of household balance sheets. Authorities have provided hundreds of billions of dollars to help complete unfinished projects, loosened down-payment requirements and lowered mortgage rates. These measures, among others, should help restore consumer confidence and minimize bankruptcies. We think government leaders have little choice but to keep introducing new policies to bolster the property market until they can rectify the situation. 


Homebuying in China has slumped 

Chart shows the annual percentage change in China home sales from 2017 through 2022. The data is represented by the quarterly sales volume of commercial residential buildings in current prices. From 2017 through 2019, home sales were in a range of 8% to 20% on an annualized basis. In the first quarter of 2020, home sales fell 23% then rebounded to rise 95% in the first quarter of 2021. They gradually declined thereafter. During 2022, home sales fell 26% in the first quarter, 32% in the second quarter, 29% in the third quarter and 28% in the fourth quarter.

Sources: Capital Group, National Bureau of Statistics of China, Refinitiv Datastream. China home sales above are represented by the quarterly sales volume of commercial residential buildings in current prices. As of December 31, 2022.

After what is likely to be a wave of consolidation and limitations on development, the property market will likely become a smaller part of the economy longer term. It should also be operated more sensibly and far less on speculation. Volume growth will likely be more measured and selling prices more constrained to make housing more affordable. This could be an opportunity for higher quality developers who have maintained stronger balance sheets to gain market share and consolidate their leadership positions.


3. Regulatory fog is clearing over China’s tech sector


The most stringent policy measures to curb overreach in China’s technology sector may be behind us. These were aimed at controlling excesses in the private economy and curbing monopolistic behavior. Moving forward, it’s clear growth for technology companies will be more constrained due to regulation but also because the industry has matured.


Valuations for internet-related companies remain depressed by historical standards. The downside seems more limited now assuming conservative earnings growth. But we do not expect a significant rerating for these companies, because revenue growth rates probably won’t reach 30% to 40% again.


On the upside, the regulatory environment appears to be improving. For example, Tencent and NetEase have received long-awaited approvals for new video game licenses. Ant Group, whose high-profile initial public offering was halted in 2020, was recently allowed to start raising capital from new investors. 


Government regulators reportedly plan to take special 1% equity stakes (known as “golden shares”) in units of Tencent and Alibaba, similar to those taken at TikTok owner ByteDance and Weibo, China’s version of Twitter. We think this signals that Beijing’s rectification process is nearing an end. 


How much risk is priced in? Tech valuations have compressed

Chart shows price-to-earnings ratios for China's largest technology-related companies. On a forward basis for the next 12 months, Tencent traded at 23 times compared to its five-year average of 34 times. Alibaba traded at 11 times versus its five-year average of 25 times. JD.com traded at 26 times compared with its five-year average of 50 times. NetEase traded at 16 times versus its five-year average of 24 times.

Sources: MSCI, RIMES. Forward price-to-earnings ratio reflects the current share price relative to the consensus estimate for earnings per share on a forward 12-month basis. Data as of November 30, 2022.

China’s internet giants have narrowed their business focus and adjusted their cost structures by exiting business lines and laying off employees. They’ve also made a massive shift in expansion and growth strategies. Instead of seeking out large-scale acquisitions, they have divested from equity stakes in other tech firms and used excess cash to buy back shares or pay special dividends to shareholders.


We believe that innovation will also continue to drive growth. China’s video game platforms, payment systems and e-commerce have been areas of tremendous innovation over the past decade, and this should continue to drive growth. As many companies find a new rhythm in the evolved regulatory regime, we expect new technologies to be new sources of revenues and earnings.


4. Beijing needs more growth to support policy agenda


It’s our belief that China wants a growing and dynamic economy characterized by a significant degree of innovation. We believe Communist Party leaders know this cannot be accomplished by state-owned businesses alone and that private enterprise is needed to achieve long-term economic goals.


China’s equity risk premium (an excess return that investing in stocks can provide over a risk-free rate typically represented by Treasuries) is higher than other markets. That’s understandable as government policy has a much greater influence on companies and industries in China than it does in most other major markets. For this reason, we expect the risk premium will remain higher. Our investment analysts incorporate regulatory risk into their analyses like they do other risks and give it the appropriate valuation. Different portfolio managers at Capital Group may take divergent views on these risks. As investors with experience in emerging markets, we believe fundamental bottom-up research can uncover opportunities while accounting for the top-down risks. 


China’s biopharmaceutical industry, which is closely aligned with the government’s domestic policy agenda, is a longer term potential opportunity with a long runway for growth. Several well-capitalized companies are developing innovative drugs that have the potential to be sold around the world. Multinationals have also partnered with Chinese firms such as BeiGene and Innovent to develop new drugs and sell them in China’s large market. 


China also wants to bolster its manufacturing prowess and retain dominance in certain areas of the global supply chain, such as electric vehicles (EVs). China has become a global leader in battery development, a key supplier of other materials and a large EV manufacturer in its own right. 


Stock picking in China has been crucial over the past decade

Chart shows price of MSCI China Index over the past decade. The price of index was 307 on December 31, 2011. It climbed to 532 on April 30, 2015. By February 29, 2016, it had fallen back to 331 before climbing back to 679 by January 31, 2018. It fell back to 486 on October 31, 2018. It rose to 841 on January 31, 2021, then declined to 351 on October 31, 2022, before rising again.

Sources: MSCI, RIMES. Data reflects price level on net basis. As of December 31, 2022. Past results are not predictive of results in future periods.

5. A reset in U.S-China relations


There have been steps in the right direction to help reset relations between the U.S. and China, which could help alleviate pressure on Chinese assets. 


Presidents Joe Biden and Xi Jinping held constructive talks at November’s G-20 meeting. U.S. audit regulators were granted deeper access to inspect the books of Chinese companies that trade on U.S. stock exchanges, helping ease concerns that the companies could be delisted. Chinese biopharmaceutical companies were also removed from the U.S. Commerce Department’s unverified list regarding access to facility inspections.


Of course, China’s strategy and approach to Taiwan remain the biggest unknown and risk.


Overall direction looking more positive


We think we are past the point of peak pessimism on China. The reopening of the economy will be a catalyst to stimulate domestic consumption, which should provide a boost to many other areas, even though the overall nominal GDP growth rate may remain muted. From our experience investing in China, the bull phase is not as strong as investor enthusiasm, and the bottom is not as deep as investors fear.


No doubt there will be ongoing geopolitical and economic uncertainties, but as the world’s second largest economy reopens, we also see many investment opportunities. Companies tapping into travel, entertainment, higher quality goods, better health care, technology innovation and renewable energy could be long-term beneficiaries. Current valuations provide good entry points for many of them. But in China as much as in any market, fundamental research and a deep knowledge of companies are a must for successful investing and determining the appropriate level of exposure.



Victor Kohn is an equity portfolio manager with 40 years of investment industry experience (as of 12/31/2023). He holds an MBA from Stanford and master’s and bachelor’s equivalent degrees in industrial engineering from the Universidad de Chile. 

Steve Watson is an equity portfolio manager with 36 years of investment industry experience (as of 12/31/23). He has an MBA and an MA in French studies from New York University as well as a bachelor's degree from the University of Massachusetts.

Kent Chan is an equity investment director with 32 years of investment industry experience (as of 12/31/2023). He holds a bachelor’s degree in political economics from the University of California, Berkeley.


Investing outside the United States involves risks, such as currency fluctuations, periods of illiquidity and price volatility. These risks may be heightened in connection with investments in developing countries. Small-company stocks entail additional risks, and they can fluctuate in price more than larger company stocks. 
 

Investing in developing markets may be subject to additional risks, such as significant currency and price fluctuations, political instability, differing securities regulations and periods of illiquidity, which are detailed in the fund's prospectus. Investments in developing markets have been more volatile than investments in developed markets, reflecting the greater uncertainties of investing in less established economies. Individuals investing in developing markets should have a long-term perspective and be able to tolerate potentially sharp declines in the value of their investments. 

 

The MSCI China Index captures large and mid cap representation across China A shares, H shares, B shares, Red chips, P chips and foreign listings (e.g. ADRs). With 714 constituents, the index covers about 85% of this China equity universe.

 

MSCI has not approved, reviewed or produced this report, makes no express or implied warranties or representations and is not liable whatsoever for any data in the report. You may not redistribute the MSCI data or use it as a basis for other indices or investment products.

Don’t miss out

Get the Capital Ideas newsletter in your inbox every other week

Investments are not FDIC-insured, nor are they deposits of or guaranteed by a bank or any other entity, so they may lose value.
Investors should carefully consider investment objectives, risks, charges and expenses. This and other important information is contained in the fund prospectuses and summary prospectuses, which can be obtained from a financial professional and should be read carefully before investing.
Statements attributed to an individual represent the opinions of that individual as of the date published and do not necessarily reflect the opinions of Capital Group or its affiliates. This information is intended to highlight issues and should not be considered advice, an endorsement or a recommendation.
All Capital Group trademarks mentioned are owned by The Capital Group Companies, Inc., an affiliated company or fund. All other company and product names mentioned are the property of their respective companies.
Use of this website is intended for U.S. residents only.
Capital Client Group, Inc.
This content, developed by Capital Group, home of American Funds, should not be used as a primary basis for investment decisions and is not intended to serve as impartial investment or fiduciary advice.